COMMUNIQUÉS West-GlobeNewswire

Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®
11/02/2019
Company now focused on completing plan to resubmit NDA in first half of 2019 PRINCETON, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a women’s healthcare company, today announced [...]
Helix BioPharma Corp. Provides Clinical Development and Strategic Corporate Update
11/02/2019
RICHMOND HILL, Ontario, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and [...]
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)
11/02/2019
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) company, today announced the completion of the first stage closing of the Acquisition [...]
Nephros Appoints Alisa Lask to its Board of Directors
11/02/2019
SOUTH ORANGE, NJ, Feb. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, [...]
TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results
11/02/2019
TYME’s novel metabolic-based investigational cancer therapy, SM-88, demonstrated encouraging results and a well-tolerated safety profile in a preliminary analysis from a Phase II study of patients with advanced [...]
Arcturus Therapeutics to Present at Upcoming Investor Conferences
11/02/2019
SAN DIEGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic [...]
Myriad Announces Prequel™ Prenatal Screen with Expanded Aneuploidy Analysis for all 23 Chromosome Pairs
11/02/2019
Enhanced Test Improves Detection of Chromosomal Abnormalities by 30 Percent(1) SALT LAKE CITY, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today [...]
Resonant Inc. Provides Update on Breakthrough XBAR™ Technology for 5G Mobile Devices
11/02/2019
First filters using XBAR™ resonators fabricated Presenting latest on XBAR this June at the International Microwave Symposium (IMS) in Boston, MA Company will be discussing its breakthrough XBAR technology at Mobile [...]
Flywheel Partners with Google Cloud to Provide Clinical Researchers with Advanced Cloud Technology and Machine Learning for Medical Imaging
11/02/2019
Breakthrough Cloud Platform and Machine Learning Technology to be Showcased at HIMSS19 in Orlando, Florida MINNEAPOLIS and MOUNTAIN VIEW, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Flywheel , provider of cloud-based [...]
Helix TCS: A Clear Market Leader in Cannabis Ancillary Services-- CFN Media
11/02/2019
SEATTLE, WA, Feb. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of [...]
Surgery Partners Announces Appointment of Eric Evans as Executive Vice President and Chief Operating Officer
11/02/2019
NASHVILLE, Tenn., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (the “Company”), a leading healthcare services company, today announced that Eric Evans has been appointed Executive Vice [...]
Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency
11/02/2019
SAN DIEGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics towards rare diseases, [...]
Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville
11/02/2019
Company Continues Long-Term, Strategic Relationship with Key Customer Recro Gainesville to be Exclusive Supplier of Ritalin LA ® and Focalin XR ® Capsules with “Total Revenue Per Capsule Economics” Expected to be [...]
Revive Closes Over 1.4 Million in Non-Brokered Private Placement
11/02/2019
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Revive Therapeutics [...]
Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
11/02/2019
New designation now includes all PNH patients WALTHAM Mass., and CRESTWOOD, Ky., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the [...]
RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2%
11/02/2019
RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2%. Consolidated revenues € 1,352.2 million, +5.0%. EBITDA (1) € [...]
Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
11/02/2019
MONTREAL, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, [...]
Clementia reçoit la désignation de « maladie pédiatrique rare » (Rare Pediatric Disease designation) de la FDA pour le palovarotène contre la fibrodysplasie ossifiante progressive
11/02/2019
MONTRÉAL, 11 févr. 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq : CMTA), une société biopharmaceutique au stade clinique proposant des traitements novateurs pour les personnes atteintes de troubles [...]
Achillion Appoints Brian Di Donato as Chief Financial Officer
11/02/2019
NEW HAVEN, Conn., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by [...]

Pages